clinical trial · NCT05305547
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
SARS-CoV-2 InfectionS-217622Placebo
brief summary
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
started
Aug 3, 2022
primary completion
Jan 7, 2024
completion
May 24, 2024
last updated
Aug 20, 2026
official title
A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol